FLT3 and acute myeloid leukemia: These findings suggest that a range of glycosylation inhibitors can decrease the glycosylation of FLT3 mutants, disrupting their plasma membrane expression and cellular signaling, providing novel insight for improving the therapeutic effect of AML treatment.